Amyloid Beta Remover Adsorbent Column for Alzheimer's Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as anti-Aβ antibody therapies, are expensive, time-consuming, and require repeated administrations, with significant side effects and short-term effects, while Aβ vaccine trials were halted due to side effects, highlighting the need for an efficient and safe method to remove amyloid β protein from the body.
Innovation Solution
Development of an amyloid β protein remover using carriers like cellulose, silica, or activated carbon with specific alkyl chain lengths or without alkyl chains, which are integrated into an extracorporeal circulation system for efficient Aβ removal from body fluids, reducing blood and intracerebral Aβ concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-Aβ antibody therapy is used, then Aβ removal effect is improved, but treatment cost increases and treatment duration is extended
Solution Approach 1:
The invention extracts the Aβ removal function from the complex anti-Aβ antibody therapy system and concentrates it into a simple extracorporeal circulation system with an adsorbent column. This separates the core function (Aβ adsorption) from the complex immune-based treatment mechanism, enabling shorter and simpler treatment courses.
Solution Approach 2:
The invention replaces the biological/immunological mechanism of anti-Aβ antibodies with a physical chemical mechanism of adsorption. The adsorbent material physically binds Aβ molecules through surface interactions, eliminating the need for complex immune response mechanisms and enabling more efficient, shorter treatment.
2Reliability
If anti-Aβ antibody therapy is used, then Aβ removal effect is improved, but treatment cost increases
Solution Approach 1:
The invention uses disposable adsorbent columns that can be easily manufactured and replaced. These columns contain adsorbent material that binds Aβ, and after use they are discarded and replaced with fresh columns. This eliminates the need for expensive, long-lasting anti-Aβ antibodies and their associated administration infrastructure.
Solution Approach 2:
The invention extracts the Aβ removal function from the complex anti-Aβ antibody therapy system and concentrates it into a simple extracorporeal circulation system with an adsorbent column. This separates the core function (Aβ adsorption) from the complex immune-based treatment mechanism, enabling shorter and simpler treatment courses.
3Reliability
If anti-Aβ antibody therapy is used, then Aβ removal effect is improved, but side effects increase
Solution Approach 1:
The invention replaces the biological/immunological mechanism of anti-Aβ antibodies with a physical chemical mechanism of adsorption. The adsorbent material physically binds Aβ molecules through surface interactions, eliminating the need for complex immune response mechanisms and enabling more efficient, shorter treatment.
Solution Approach 2:
The adsorbent column acts as an intermediary between the blood and the Aβ removal process. Instead of using antibodies that actively attack and cause immune responses, the adsorbent passively binds Aβ molecules as they pass through the column, minimizing harmful immune reactions while effectively removing Aβ.
4Reliability
If anti-Aβ antibody therapy is used, then Aβ removal effect is improved, but administration frequency increases
Solution Approach 1:
The extracorporeal circulation system with adsorbent column can operate continuously or for extended periods, maintaining constant Aβ removal capability. The system allows for prolonged treatment sessions without the need to stop and restart, providing continuous therapeutic action that reduces the number of separate administrations required.
Solution Approach 2:
The invention replaces the biological/immunological mechanism of anti-Aβ antibodies with a physical chemical mechanism of adsorption. The adsorbent material physically binds Aβ molecules through surface interactions, eliminating the need for complex immune response mechanisms and enabling more efficient, shorter treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a cost-effective, rapid, and minimally invasive method for Aβ removal with reduced side effects, capable of significantly decreasing Aβ concentrations in the blood and brain, offering a promising therapeutic or preventive approach for Alzheimer's disease.
Implementation Method 1
Aβ adsorption abilities (removal abilities) of existing medical adsorbing materials were evaluated in comparison
Implementation Method 2
an adsorbent obtained by covering a surface of a bead-like activated carbon with a hydrophilic polymer
Data Source
AI summary
An object is to provide a material capable of removing Aβ from a body fluid efficiently and use of the material, which are developed for the purpose of establishing a therapeutic or preventive method for Alzheimer's disease. Provided is an amyloid β protein remover, containing a carrier made of any one material selected from the group consisting of cellulose, silica, polyvinyl alcohol, and activated carbon, wherein the carrier does not have an alkyl chain on the surface thereof or has an alkyl chain having 1 to 18 carbon atoms on the surface thereof.